Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
Takeda
Merck Sharp & Dohme LLC
Centre Hospitalier Universitaire Dijon
Fondazione Italiana Linfomi - ETS
Memorial Sloan Kettering Cancer Center
Fondazione Italiana Linfomi - ETS
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC